Acylin Corporation is the first company focused on developing inhibitors of cellular acylation, an enzymatic mechanism fundamental to the molecular pathology of cancer, metabolic disease, and neurodegeneration. Acylin was founded in 2009 by Boston based entrepreneurs Suresh Jain, Ph.D. and Peter Distefano, PhD, along with scientific co-founders Philip A. Cole, M.D., Ph.D. at Johns Hopkins University School of Medicine and Ronen Marmorstein, Ph.D. at The Wistar Institute. Recent discoveries by Acylin founders and other investigators have revealed protein acetylation (the two-carbon and most common form of acylation) as a cellular signal transduction regulator potentially as ubiquitous and important as kinases/phosphorylation. The Company has developed a platform technology to design specific acyltransferase inhibitors based on crystal structures, novel medicinal chemical approaches and mechanistic understanding. Acylin has prioritized the CBP/p300 (a member of the Histone Acetyl Transferase [HAT] class) and Ghrelin O-Acyl Transferase (GOAT) for initial drug discovery.

Portfolio Home